ArticleBMC medical imaging2025
Automated pancreatic extracellular volume fraction as a biomarker for microangiopathy in type 2 diabetes mellitus.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo develop noninvasive, opportunistic screening methods using routine abdominal enhanced CT imaging to derive an automated pancreatic extracellular volume fraction (AP-ECV) as a novel biomarker for evaluating microangiopathy in type 2 diabetes mellitus (T2DM).
methodsA retrospective study was conducted on 320 patients with T2DM who underwent routine enhanced abdominal CT examinations. Microangiopathy refers to retinopathy, nephropathy or peripheral neuropathy in patients with diabetes. An automated method was developed to calculate AP-ECV values from enhanced abdominal CT images. The association between AP-ECV and T2DM microangiopathy was evaluated using univariate and multivariate logistic regression analyses. Then, assess the sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) for AP-ECV's diagnostic ability in T2DM microangiopathy. Ordinal logistic regression estimated risk factors associated with the severities of microangiopathy, categorized into three levels.
resultsAP-ECV and T2DM duration significantly increased in T2DM patients with microangiopathy (p < 0.01). The AUC for AP-ECV and T2DM duration were 0.767 and 0.761, respectively, with a combined AUC of 0.881. As AP-ECV increased (OR 1.406) and T2DM duration lengthened (OR 1.163), microangiopathy severity significantly escalated.
conclusionAP-ECV is a potential imaging biomarker for T2DM microangiopathy, offering a valuable noninvasive diagnostic tool benefitting early management in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.